Malcolm Qualie, pharmacy lead, specialised services at NHS England, says incentives to switch to biosimilars could help reduce the pressure on NHS budgets. Speaking in London at the Ethical ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

To read all of these articles and more, visit centerforbiosimilars.com.

At the same time, 90% of U.S. prescriptions are either generics or biosimilars saving the U.S. healthcare system $445 billion in 2023 alone. Despite these achievements, there are important reforms ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar during ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Patients who have been on Inflectra can continue their therapy without any need to switch between different biosimilars, ensuring consistency in their care during this transition.” Celltrion ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.